Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10678782 | 0.89 | TBXAS1 (0.33) | CAPN1 | |
| SCHEMBL8465150 | 0.87 | TBXAS1 (0.36) | — | |
| SCHEMBL6532553 | 0.87 | TBXAS1 (0.36) | — | |
| SCHEMBL2704416 | 0.82 | CHRM1 (0.39) | — | |
| SCHEMBL806181 | 0.79 | — | — | |
| SCHEMBL4811573 | 0.76 | TSHR (0.41) | — | |
| SCHEMBL18839751 | 0.76 | LMNA (0.35) | — | |
| SCHEMBL4671779 | 0.75 | — | — | |
| SCHEMBL1650867 | 0.74 | TBXAS1 (0.41) | — | |
| SCHEMBL1260251 | 0.74 | CYP2C9 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170876-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTINTION AND TREATMENT OF RESTENOSIS COMPRISING ISOXAZOLE DERIVATIVES | SK Holdings Co., Ltd. (KR) | 2010-04-07 | — | — | EP | claimed |
| WO-2009005269-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTINTION AND TREATMENT OF RESTENOSIS COMPRISING ISOXAZOLE DERIVATIVES | SK HOLDINGS CO., LTD. (KR) | 2009-01-08 | — | — | WO | claimed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | claimed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | claimed |
| US-11365199-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | MERCK PATENT GMBH (DE) | 2022-06-21 | — | — | US | disclosed |
| EP-3013832-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| US-20180354965-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-12-13 | — | — | US | disclosed |
| US-9839642-B2 | Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3139918-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015171474-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | WO | disclosed |
| EP-2397477-B1 | Heterocyclic-substituted piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20070200089-A1 | Polishing liquid for metals | FUJIFILM CORPORATION | 2007-08-30 | — | — | US | disclosed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
| US-7001901-B2 | Tetrazolylpropionamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-7001901-B2 | Tetrazolylpropionamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-7001901-B2 | Tetrazolylpropionamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365199-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | FSHR, GNRHR, LHCGR | CAPN1 3587/4885 |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MGAM, CMBL, PEPD | CAPN1 531/4885 |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | APP, APBA1, DNPEP | CAPN1 1460/4885 |
| US-20180354965-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | CAPN1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.